Hims & Hers posts $92M Q1 loss as weight-loss pivot drives up costs; expands platform via acquisitions

Hims & Hers Health (NYSE: HIMS) reported a net loss of $92.1 million for the first quarter of 2026, missing analyst estimates on both revenue and earnings. Shares fell approximately 15% in premarket trading on 12 May 2026. The company attributed the loss largely to costs associated with its pivot toward weight-loss care and GLP-1 drug offerings, which have required significant investment to build out infrastructure, sourcing, and provider capacity.

Hims & Hers operates a direct-to-consumer telehealth platform spanning multiple conditions including erectile dysfunction, hair loss, testosterone optimisation, mental health, and weight management. The company distributes care via subscription-based provider consultations and an affiliated pharmacy network. In recent periods it has expanded internationally through ZAVA, a European telehealth provider, and Livewell, a UK-based digital health brand.

Despite the earnings miss, management raised full-year guidance, citing expectations of improved performance tied to a newly announced partnership with Novo Nordisk. The company also disclosed meaningful portfolio moves: it integrated GRAIL's multi-cancer early detection testing into its platform and completed the acquisition of YourBio Health, a developer of advanced at-home blood sampling technology. These additions extend Hims & Hers' service offering well beyond its original direct-to-consumer prescription categories.

The Q1 results illustrate the financial cost of strategic pivoting at scale. Transitioning a consumer health platform into adjacent high-cost categories such as GLP-1 therapy requires upfront investment in supply chains, regulatory compliance, and provider networks that compress near-term margins. The Novo Nordisk partnership and raised guidance suggest the company believes this cost curve will normalise — but the $92.1M quarterly loss underscores the execution risk of broad-platform ambitions. For the mentech sector, Hims & Hers remains the most visible publicly listed benchmark, and its ability to absorb this transition will set expectations for similar platform-model health companies.